15 Steps to Helping Psychiatric Patients Achieve and Maintain a Healthy Weight

Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.

A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.

Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.

Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.

New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.

How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.

Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.